Infectious Diseases and Immunity in Global Health Program (IDIGH) has been developed at McGill University to maximize the research effort with a translational focus. We are proud to sponsor their yearly symposium which will be held on Friday, October 19, 2018. In so doing, MédiMabs affirms its continuity in bringing new products on the market and in developing de novo antibodies with research partners in the field of infectious diseases.
Amongst them, we offer a larger variety of reagents to study HIV-1 viral particles (gp120 (V2, V3, C2 and CD4bs) and gp41), to identify infected cells (p24) and assess the cellular pathways harnessed by the virus (PACT, DICER, TRBP). In addition to other reagents antibodies against Pseudomonas aeruginosa, Herpes virus, Leishmania we also have antibodies against receptors implied in the pathogen recognition and immune system activation like Dectin-2 and the recently added CCAB-series anti-TLR4.
We wish to all the attendees, a great symposium.